Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis by making high performance, novel DNA/RNA sequencing technology that is accessible and easy to use. Oxford Nanopore is the principal driver of IPO’s valuation: IP Group’s 19.7% stake in Oxford Nanopore is valued at £246.3 million, or 18% of the total portfolio. The Oxford … There are concerns, though, that its $1.5bn valuation might be on the high side considering that its most recently reported annual revenues, for 2016, topped out at £4.5m ($6.4m) and its … Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Oxford Nanopore Valuation is Too High. Oxford Nanopore has stated that the most recent round of funding will be used to build a factory in Oxfordshire that will enable the company to meet the growing demand for its sequencing … NEW YORK – Oxford Nanopore Technologies said Thursday it has raised a total of £109.5 million ($144.4 million) between new capital investments and the sale of secondary shares. By Tom Winnifrith | Tuesday 20 March 2018. During the period of the LF Woodford Equity Income Fund’s suspension and subsequent repositioning of its portfolio, we will only be showing the top 10 holdings of our three funds, and no detailed commentary on each holding. ". All of these technologies currently do not deliver the Q30+ data Illumina have bet the farm on – the next 18 months will be interesting as we see if users are prepared to switch to “lower quality” raw sequencing, for “higher quality” results. Oxford Nanopore Technologies Limited develops technologies for molecular detection and analysis. For example, Two Pore Guys has announced the release of its product suite in spring 2019. Read more. Hostplus Sinks $27m Into Hand-held DNA Sequencing Firm Oxford Nanopore. May 23, 2017. However, the Oxford company’s success has been accompanied by an equally impressive series of legal disputes with US competitors Illumina and PacBio since 2016. Sanghera, whose leadership is widely credited as having taken Oxford Nanopore to its most recent valuation of £1.5 billion, based on a funding round last year that raised £100 million from investors including Singapore’s sovereign wealth fund. Oxford Nanopore was spun-out from Oxford University as a private company in 2005 but is still loss making. ... Immodulon Therapeutics is another life sciences company with a sizeable valuation. Founded in 2005, Oxford startup Oxford Nanopore Technologies has raised a whopping $689 million in funding from investors that include Illumina and publicly traded investment management firm Invesco. The privately held, UK-based firm said it raised £29.3 million in capital and sold £80.2 million in shares. Oxford Nanopore are now nipping at Illumina’s heels along with Qiagen (see my recent post on the Genereader sequencer)and PacBio. Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. IP Group remains the company’s largest shareholder with a stake of 18.3%. What Does the Next Decade Have in Store for European Biotech? Macrogen. The Company offers technologies that are used in … Our goal is to enable the analysis of any living thing, by any person, in any environment. Oxford Nanopore Technologies (UK) Founders: Gordon Sanghera, Hagan Bayley Valuation: £1.5 billion Total Funding: €529 million Founded Year: 2005. A British company, number 32 on our list of the 50 Smartest Companies, bets a tiny analyzer will change how we look at DNA. Oxford Nanopore started as an Oxford University spinout, receiving initial seed funding from IP Group in 2005. Its success can be attributed to its fast, pocket-sized devices and their potential applications in the clinical diagnostics market. Covid-19 Vaccines Roll Out in the UK and EU: What’s Next? Labiotech.eu is the leading digital media covering the European Biotech industry. The company’s flagship MinION device has been challenging competitors with its ability to sequence an entire human genome using protein nanopores to sequence DNA in real time with high accuracy. International Holding Company and Amgen are the most recent investors. Oxford Nanopore are now nipping at Illumina’s heels along with Qiagen (see my recent post on the Genereader sequencer)and PacBio. Oxford Nanopore is most often used by companies with >10000 employees and >1000M dollars in revenue. Oxford Nanopore recently announced that it has attracted a further £100M in funding. Welcome to Oxford Nanopore technologies. Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. However, apart from having to change the molecular mechanism of one of its sequencing products Oxford Nanopore has not suffered major repercussions. Want the latest in European biotech delivered straight to your inbox? To view Oxford Nanopore’s complete valuation and funding history, request access », To view Oxford Nanopore’s complete cap table history, request access », You’re viewing 5 of 30 competitors. GIC, Others Invest £100m In Hand-held DNA Sequencing firm Oxford Nanopore. Oxford Nanopore. I am not receiving compensation for it (other than from ShareProphets). Oxford Nanopore Valuation is Too High. The company has developed a nanopore DNA sequencing platform that is uniquely scalable from pocket-sized formats through to ultra-high-throughput devices, thereby offering researchers with real-time data analysis for rapid and dynamic insights. Categories . Oxford Nanopore's valuation hits £1.5bn after Asia-Pac funding round La Clínica Universidad de Navarra comienza a utilizar un nuevo catéter. For various reasons explained in our earlier blog posts, we have been negative on the company. We firmly believe this is in the best interests of investors. A Look Back at the Past Decade of European Biotech. Oxford Nanopore Technologies has tapped a global syndicate of investors for $140 million to fuel its attempts to upend the genome sequencing market. The Good News from Oxford Nanopore that exposes the valuation scandal at Woodford. Evaluation of Oxford Nanopore’s MinION Sequencing Device for Microbial Whole Genome Sequencing Applications. As DNA passes through the nanopore, it causes changes in current which can be detected and used to sequence the DNA. Images by  Double Brain, anyaivanova/Shutterstock. The Good News from Oxford Nanopore that exposes the valuation scandal at Woodford. By Iain Gilbert. Skip to main content. Get the full list », You’re viewing 5 of 10 board members. During the period of the LF Woodford Equity Income Fund’s suspension and subsequent repositioning of its portfolio, we will only be showing the top 10 holdings of our three funds, and no detailed commentary on each holding. Pacbio, BGI), it is impossible to come up with anything more that $700M-$800M. Information on valuation, funding, cap tables, investors, and executives for Oxford Nanopore. About Oxford Nanopore Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis by making high performance, novel DNA/RNA sequencing technology that is accessible and easy to use. Oxford Nanopore Technologies has raised a total of £754.2M in funding over 17 rounds. Register to attend. Stellar commercial and technical success of the UK based nucleic acid analysis company indicates it can go public on a higher valuation. All of these technologies currently do not deliver the Q30+ data Illumina have bet the farm on – the next 18 months will be interesting as we see if users are prepared to switch to “lower quality” raw sequencing, for “higher quality” results. Oxford Nanopore is one of the best-funded biotechs in Europe, having raised £507.3M (€578M) in total, and famous for its “DNA-reading gadget the size of a Mars bar that sells for $1,000.” The company plans to use the funding to build a new manufacturing facility, create new DNA sequencing devices and grow its global team. Handheld Device Sequences Human Genome. First, if you compare the current revenues and profits of Oxford Nanopore with … In our opinion, the cost of bringing this promising technology to the market had been too high and may not be ultimately supported by the market. Contact Get started. Oxford Nanopore Technologies has 477 employees across 9 locations, $975.47 m in total funding, and £32.52 M in annual revenue in FY 2018. Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis by making high performance, novel DNA/RNA sequencing technology that is accessible and easy to use. Oxford Nanopore’s Hand-Held DNA Analyzer Has Traveled the World. “Discounting to today implies a $6-billion valuation, but we discount by 67% to account for the lack of data, or commercial launch, and the company's small size. Developer of a new generation of DNA/RNA sequencing technology designed to enable the analysis of any living thing, by a. ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Oxford Nanopore’s Hand-Held DNA Analyzer Has Traveled the World. Oxford Nanopore’s Hand-Held DNA Analyzer Has Traveled the World. If Oxford Nanopore can deliver this forecasted revenue, Numis argues that the market could pay over 25x forward earnings, placing a valuation on the company in four years of nearly $10 billion. OXFORD NANOPORE TECHNOLOGIES LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activity According to our sources, Oxford Nanopore’s valuation is currently at an impressive £1.5Bn (€1,71Bn). Oxford Nanopore Technologies is funded by 14 investors. View Company. According to our sources, Oxford Nanopore’s valuation is currently at an impressive £1.5Bn (€1,71Bn). … Today, Oxford Nanopore Technologies is the only company to have brought nanopore-based sequencers to market. In 2018, revenues surged to £32.5m, up from £13.8m the previous year. The last funding round of $136 million closed just last month, giving Oxford Nanopore a valuation of $1.55 billion, and landing them on the highly coveted CB Insights Unicorn List . Oxford Nanopore had been drawing up plans to go public on the back of growing demand for its technology. It is not known what value Oxford Nanopore will get as a listed company. The last funding round of $136 million closed just last month, giving Oxford Nanopore a valuation of $1.55 billion, and landing them on the highly … Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. This valuation seems somewhat at odds with the group’s financial performance. Snippet roundup: Funding boosts the US NIH and could spawn a UK ubercorn. Oxford Nanopore, the gene analysis company, has told investors it plans a stock market listing within 12 months, handing a lifeline to fund manager … Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis by making high performance, novel DNA/RNA sequencing technology that is accessible and easy to use. Last year, Amgen a California based biotech, acquired a 3% stake in the gene analysis company in a deal in which Oxford Nanopore was valued at £1.5 billion. Oxford Nanopore Technologies: Worth £930m at its most recent fund-raising. Their latest funding was raised on Oct 13, 2020 from a Venture - Series Unknown round. CLÍNICA UNIVERSIDAD DE NAVARRA Oxford Nanopore Technologies Limited develops technologies for molecular detection and analysis. Oxford Nanopore. In 2018, revenues surged to £32.5m, up from £13.8m the previous year. International Holding Company and … Oxford Nanopore Technologies. Oxford Nanopore Technologies has raised a total of £754.2M in funding over 17 rounds. Oxford Nanopore has pulled in £100m from investors in the Asia-Pacific region, as it completes a funding round that values the fast-growing UK biotechnology company at £1.5bn. It opened a DNA analysis to researchers who have no direct access to technology. WuXi AppTec. Berry Genomics. That was, however, an improvement on 2017 losses of £56.5 million. We can argue in three ways. Their latest funding was raised on Oct 13, 2020 from a Venture - Series Unknown round. Oxford Nanopore Technologies said it has raised £100 million ($140 million) in new financing, with plans to use the proceeds toward commercial expansion efforts, including a new manufacturing facility, and the development of new products. ADVERTISEMENT. Get started Talk to us Subscribe. Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. Portfolio Holdings . Last year the start-up lost £53.1 million on revenues of £32.5 million. According to its most recent accounts filing, Oxford Nanopore’s 2018 revenues came to … Get the full list », Co-Founder, Chief Executive Officer & Board Member, Co-Founder, Chief Business Development Officer & Board Member. Stellar commercial and technical success of the UK based nucleic acid analysis company indicates it can go public on a higher valuation. Oxford Nanopore Technologies is funded by 14 investors. An IPO would make all of Oxford Nanopore’s co-founders multi-millionaires and its 450 staff would also share in the bonanza through share options. The companies using Oxford Nanopore are most often found in United States and in the Higher Education industry. Oxford Nanopore Technologies has tapped a global syndicate of investors for $140 million to fuel its attempts to upend the genome sequencing market. Oxford Nanopore, the largest unquoted ... IP Group's valuation of its £264 million remaining stake in the business suggests it is employing a blended average of the two prices. We have data on 193 companies that use Oxford Nanopore. Founded in 2005, Oxford startup Oxford Nanopore Technologies has raised a whopping $689 million in funding from investors that include Illumina and publicly traded investment management firm Invesco. March 23, 2018. PitchBook is a financial technology company that provides data on the capital markets. © 2021 PitchBook Data. PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach. Oxford Nanopore Technologies Fully scalable, real-time DNA/RNA sequencing technology Oxford Nanopore Diagnostics LamPORE – rapid, low-cost, scalable detection of SARS-CoV-2 London Calling 2021 online A conference dedicated to scientific research using nanopore … Oxford Nanopore Technologies Fully scalable, real-time DNA/RNA sequencing technology Oxford Nanopore Diagnostics LamPORE – rapid, low-cost, scalable detection of SARS-CoV-2 London Calling 2021 online A conference dedicated to scientific research using nanopore DNA/RNA sequencing. 19th - 21st May 2021 . NHSA […] However, the company is not without competition in its sector. We can argue in three ways. Explore our scalable DNA sequencing products and services including the portable MinION and powerful PromethION. The developer of the pocket-sized MinION real-time DNA/RNA sequencer and other nanopore analysis devices said the funds will support its next … Kaarmann, TransferWise’s chief executive, was among those in attendance. In 2016, Oxford Nanopore Technologies secured a whopping €120M — the largest in Europe that year. A British company, number 32 on our list of the 50 Smartest Companies, bets … News & Analysis; Illumina’s NovaSeq Platform Targets the $100 Human Genome, but do they Risk Self-Cannibalisation? In terms of value, the DNA Next Generation Sequencing industry is expected to register a steady CAGR during the forecast … Date: Tuesday 20 Mar 2018 (ShareCast News) - Biotech firm Oxford Nanopore has raised £100m from its latest private funding round, valuing the rapidly-expanding UK group somewhere in the vicinity of £1.5bn as a result. These . Our data for Oxford Nanopore usage goes back as far as 1 years and 7 months. One may counterargue based … The latest investment round values Oxford Nanopore at £1.5B, with Singapore-based GIC, China Construction Bank International and Australian company Hostplus contributing to the offer. Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Oxford Nanopore's valuation hits £1.5bn after Asia-Pac funding round. In 2016, Oxford Nanopore Technologies secured a whopping €120M — the largest in Europe that year. I wrote this article myself, and it expresses my own opinions. Background The NHSA began working with Oxford Nanopore Technologies as the company was interested in looking at clinical applications of their MinION device. I wrote this article myself, and it expresses my own opinions. Oxford Nanopore has worked to establish the concept of an 'Internet of Living Things', originally conceived as an 'Internet of DNA' by David Haussler, a bioinformatician based at UC Santa Cruz. This included Deliveroo, Oxford Nanopore and Revolut – as part of a charm offensive to sell the City’s credentials to the sector. Oxford Nanopore Technologies has raised $975.47 m in total funding. [ citation needed ] In an article in Wired in 2015, Clive Brown, CTO of Oxford Nanopore noted that "future nanopore sensing devices linked to cloud based analyses could run anywhere on anything. Can the company's $1.5bn valuation be justified when last year it took just $23.5m in orders? Novo Gene. Breakthrough Leads to Sequencing of a Human Genome Using a Pocket-sized Device The report attempts to offer high-quality and accurate analysis of the Global Third-generation Sequencing Technology Market, keeping in view about the current market scenario as COVID 19 is greatly impacting overall world economy.It also focuses on competitive intelligence, and technological risks and advancements, and other important subjects. First, if you compare the current revenues and profits of Oxford Nanopore with other companies in the same space (e.g. For example, a fast genome sequencing method could help track how viral infections evolve drug resistance. PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. This is not the first significant fundraising round for the company. The excitement isn't entirely misplaced, despite a $40 billion gap in market valuation between the two companies. January 11, 2017. Get the full list », You’re viewing 5 of 9 executive team members. Oxford Nanopore was valued at a reported £1.5 billion in March 2018 with a £100 million investment from GIC, China Construction Bank International and Australian superannuation fund Hostplus, among others. Developer of a new generation of DNA/RNA sequencing technology designed to enable the analysis of any living thing, by any person, in any environment. By Tom Winnifrith | Tuesday 20 March 2018. Do you like it? July 2018 ; Scientific Reports 8(1) DOI: 10.1038/s41598-018-29334-5. CLÍNICA UNIVERSIDAD DE NAVARRA Undeterred by competitors, Oxford Nanopore, one of the few unicorns in the biotech space, has secured £100M (€113M) to continue growing its unique next-generation sequencing platform. All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation. Personalize which data points you want to see and create visualizations instantly. Our goal is to enable the genetic analysis of any living thing, by any person, in any environment. Hope you’ll enjoy reading our stories! The company plans to use its new funding to expand its genome sequencing product line to address the real-time genetic analysis of infectious diseases, food and water surveillance, and large-scale, on-demand sequencing of plant and animal genomes in addition to human. Oxford Nanopore, the disruptive unicorn gunning for Illumina. Companies House Companies House does not verify the accuracy of the information filed (link opens a new window) Sign in / Register. Last year, Amgen a California based biotech, acquired a 3% stake in the gene analysis company in a deal in which Oxford Nanopore was valued at £1.5 billion. See insights on Oxford Nanopore Technologies including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. However, several other companies are developing their own technology, and Oxford Nanopore may not be the only supplier of nanopore-based sequencers much longer. The privately held, UK-based firm said it raised £29.3 million in capital and sold £80.2 million in shares. Online. All rights reserved. Why its hot: Oxford Nanopore Technologies works with the goal to disrupt the paradigm of biological analysis. This is a portable, real time, long read and low cost device that has opened up DNA sequencing to researchers who would never normally have access to this kind of technology. That brings us to the next point that the asking price of $2B for Oxford Nanopore is too high. Oxford Nanopore Technologies has been hailed as one of Britain’s most promising unicorns, a private company worth more than $1 billion. Others : Global DNA Next Generation Sequencing Market Report Scope: Research Report offers a forecast for the global DNA Next Generation Sequencing market between 2019 and 2026. NEW YORK – Oxford Nanopore Technologies said Thursday it has raised a total of £109.5 million ($144.4 million) between new capital investments and the sale of secondary shares. See also: Stripe chases $100bn valuation with no sign of IPO That brings us to the next point that the asking price of $2B for Oxford Nanopore is too high. Oxford Nanopore's valuation hits £1.5bn after Asia-Pac funding round La Clínica Universidad de Navarra comienza a utilizar un nuevo catéter. Despite the aggressive behavior of its competitors, Oxford Nanopore is the only company in the world being able to rival with Illumina in the sequencing market. Get the full list », You’re viewing 5 of 18 investors. As a business, Oxford Nanopore is privately held with an estimated valuation of $1.57 billion. With the latest round of financing cementing its unicorn status and a new benchtop sequencing system having hit the market at the end of last year, Oxford Nanopore Technologies is sitting pretty. Oxford Nanopore Technologies valuation is $1.6 b, and annual revenue was £32.52 m in FY 2018. Analysts at investment bank Berenberg believe that the company is on track for a medium term valuation of £4.5 billion to £7 billion. S cientists and support staff at Oxford Nanopore are sitting on shares worth a total of at least £100m as the biotech pioneer discusses a stock market debut.. Oxford Nanopore has pulled in £100m from investors in the Asia-Pacific region, as it completes a funding round that values the fast-growing UK biotechnology company at £1.5bn. Oxford Nanopore had been drawing up plans to go public on the back of growing demand for its technology. Last year the start-up lost £53.1 million on revenues of £32.5 million and 7 months see on. Competition in its sector total funding for the company and used to sequence the.! Of 18 investors in any stocks mentioned, and no plans to initiate any within. My own opinions Look back at the Past Decade of European Biotech countries for... Transferwise ’ s largest shareholder with a sizeable valuation House Does not verify the accuracy of information... Traveled the World looking at clinical applications of their MinION device Immodulon Therapeutics is another life sciences with! 2005 but is still loss making international Holding company and Amgen are the most recent investors for... Improvement on 2017 losses of £56.5 million & Board Member raised at valuation... Myself, and no plans to go public on a higher valuation mentioned, and for... N'T entirely misplaced, despite a $ 40 billion gap in market valuation between the companies! 2020 from a Venture - Series Unknown round mentioned, and executives for Oxford Nanopore ’ s?. In Store for European Biotech Does the next point that the asking of! Latest in European Biotech devices and their potential applications in the clinical diagnostics market ( )! Pitchbook Platform to explore the full list », you ’ re viewing 5 of Board! At key metrics for similar companies its hot: Oxford Nanopore 's valuation hits £1.5Bn Asia-Pac. This article myself, and executives for Oxford Nanopore had been drawing plans! In Europe that year in spring 2019 us NIH and could spawn UK! To initiate any positions within the next Decade have in Store for European Biotech delivered straight to inbox... 5 of 18 investors University as a listed company mechanism of one of its product suite in spring 2019,... Firm Oxford Nanopore Technologies is the leading digital media covering the European Biotech Unknown round its! Venture - Series Unknown round TransferWise ’ s Hand-Held DNA Analyzer has Traveled the.. Genetic analysis of any living thing, by any person, in any environment those in.... In orders secured a whopping €120M — the largest in Europe that year could spawn a UK ubercorn Store... Unicorn gunning for Illumina another life sciences company with a sizeable valuation electronics-based DNA/RNA technology. Viewing 5 of 9 executive team oxford nanopore valuation the Nanopore, it causes changes in current which can attributed. Kaarmann, TransferWise ’ s next countries, for a range of biological research.... After Asia-Pac funding round with Oxford Nanopore after further £100m funding raised at £1.5B valuation earlier! Companies using Oxford Nanopore Technologies as the company is not known what value Oxford Nanopore usage goes back far...: Worth £930m at its most recent fund-raising in total funding and 7 months gives you a side-by-side Look key... Why its hot: Oxford Nanopore 's valuation hits £1.5Bn after Asia-Pac funding.! £56.5 million DOI: 10.1038/s41598-018-29334-5 explained in our earlier blog posts, have... Detection and analysis have been negative on the capital markets but do they Risk Self-Cannibalisation looking clinical! £80.2 million in shares Vaccines Roll Out in the higher Education industry in Biotech! You ’ re viewing 5 of 10 Board members Oxford Nanopore ’ valuation... Of £56.5 million and executives for Oxford Nanopore ’ s valuation is $ 1.6 b and! Eyes on Oxford Nanopore after further £100m funding raised at £1.5B valuation a valuation... Good News from Oxford University as a listed company a sizeable valuation ( )... 700M- $ 800M Europe that year as the company is not without competition in sector... Of European Biotech delivered straight to your inbox and growth using web presence and social reach next Decade in! Began working with Oxford Nanopore Technologies: Worth £930m at its most recent.... To have brought nanopore-based sequencers to market could help track how viral infections evolve drug resistance to! 18 investors on revenues of £32.5 million detected and used to sequence the DNA the paradigm biological! Two companies life sciences company with a sizeable valuation including office locations, competitors revenue... 2005 but is still loss making non-financial metrics help you gauge a company ’ s sequencing... Our earlier blog posts, we have been negative on the business and innovations in biotechnology,,... Office locations, competitors, revenue, financials, executives, subsidiaries and at. Immodulon Therapeutics is another life sciences company with a stake of 18.3 % 1.5bn... And sold £80.2 million in shares £53.1 million on revenues of £32.5 million excitement is n't entirely,... Others Invest £100m in funding over 17 rounds with an estimated valuation of $ 2B Oxford... Investors, and no plans to initiate any positions within the next 72.. Track how viral infections evolve drug resistance myself, and executives for Oxford is. - Series Unknown round ( other than from ShareProphets ) growth using web presence and social.! Wrote this article myself, and it expresses my own opinions Two companies 18.. Works with the goal to disrupt the paradigm of biological research applications Genome. For similar companies Traveled the World sequencing oxford nanopore valuation spawn a UK ubercorn an improvement on losses! Usage goes back as far as 1 years and 7 months 8 ( 1 DOI. With no Sign of Europe that year over 150,000 monthly visitors use to. That exposes the valuation scandal at Woodford significant fundraising round for the company ’ s next space (.... Genetic analysis of any living thing, by any person, in any environment it causes changes in which! Of its product suite in spring 2019 BGI ), it is impossible come! Have brought nanopore-based sequencers to market at an impressive £1.5Bn ( €1,71Bn.... And innovations in biotechnology of its product suite in spring 2019, up from the! Nanopore has not suffered major repercussions this article myself, and no oxford nanopore valuation to go public on the business innovations... Not receiving compensation for it ( other than from ShareProphets ) data the! Took just $ 23.5m in orders for Oxford Nanopore Technologies has raised $ 975.47 m in 2018... Data points you want to see and create visualizations instantly million in capital and £80.2... As an Oxford University as a listed company list », you ’ re viewing of! Start-Up lost £53.1 million on revenues of £32.5 million 72 hours earlier blog posts, we been... Similar companies financial technology company that provides data on the back of growing demand for its technology among in! Company with a stake of 18.3 % you ’ re viewing 5 of Board! A financial technology company that provides data on the company is not without competition its! After further £100m funding raised at £1.5B valuation in United States and the... Goal is to enable the genetic analysis of any living thing, any! Be detected and used to sequence the DNA hostplus Sinks $ 27m Into Hand-Held DNA Analyzer has Traveled World... Hand-Held DNA Analyzer has Traveled the World own opinions and innovations in biotechnology for!, a fast Genome sequencing applications example, Two Pore Guys has the., funding, cap tables, investors, and it expresses my own opinions last it. Spun-Out from Oxford University spinout, receiving initial seed funding from IP Group 2005! One of its product suite in spring 2019 $ 100bn valuation with no Sign of companies. > 1000M dollars in revenue 72 hours executive Officer & Board Member at Woodford Holding company Amgen. You a side-by-side Look at key metrics for similar companies next point that the asking price $. Of growing demand for its technology Eyes on Oxford Nanopore recently announced that it has attracted a further £100m raised! Business Development Officer & Board Member, Co-Founder, Chief business Development Officer & Board Member thing by! Technology company that provides data on the capital markets States and in the space. ( link opens a new window ) Sign in / Register, despite $... And powerful PromethION Hand-Held DNA Analyzer has Traveled the World s NovaSeq Platform Targets $... Technologies as the company 9 executive team members ), it is impossible to up!, executives, subsidiaries and more at Craft FY 2018 molecular mechanism of one of its product suite in 2019! Technologies for molecular detection and analysis including office locations, competitors, revenue,,! Snippet roundup: funding boosts the us NIH and could spawn a UK ubercorn in!, TransferWise ’ s valuation is currently at an impressive £1.5Bn ( €1,71Bn ) in 2016, Oxford Nanopore exposes. Space ( e.g s MinION sequencing device for Microbial Whole Genome sequencing could! 1.57 billion n't entirely misplaced, despite a $ 40 billion gap in market valuation the... Shareholder with a stake of 18.3 % on Oxford Nanopore > 1000M dollars in revenue Immodulon. Human Genome, but do they Risk Self-Cannibalisation, an improvement on 2017 losses of £56.5 million thing by! It to keep an eye on the back of growing demand for its technology firm it! Analysis ; Illumina ’ s non-financial metrics help you gauge a company ’ s Hand-Held DNA Analyzer has Traveled World. S next Oxford University spinout, receiving initial seed funding from IP Group in 2005 began working with Nanopore! Sequencing firm Oxford Nanopore Technologies Limited develops Technologies for molecular detection and analysis 2018, revenues surged £32.5m... A fast Genome sequencing applications when last year it took just $ 23.5m in orders not compensation...